elongation factor for RNA polymerase II 3Genealiases: []
Q-omics provides the consensus-scored ELL3 profile across patient tissues and cancer cell-line models. ELL3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ELL3 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, ELL3 RNA expression shows 18,433 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, LIHC, and ACC as cancer lineages where ELL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELL3 survival associations across molecular data types. ELL3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELL3 RNA expression–survival associations across cancer types. High ELL3 expression shows unfavorable associations in LGG, ACC, MESO, KICH and LIHC, but favorable associations in READ. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify READ as the clearest survival context for ELL3 RNA expression.
This table summarizes ELL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ELL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELL3 shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, LUAD, BRCA and LUSC. The LIHC box plot shows higher ELL3 RNA expression in tumor versus normal tissue (log2 FC = +0.266, t-test p < 0.001).
This table shows molecular features associated with ELL3 in patient tissues and cancer cell lines. In patient samples, ELL3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ELL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
